Better Therapeutics, Inc. (BTTX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 22, 2025, 2:53 PM EDT

Better Therapeutics Company Description

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases.

The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes.

It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.

In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease.

Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease.

The company was founded in 2015 and is headquartered in San Francisco, California.

Better Therapeutics, Inc.
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees54
CEOFrank Karbe

Contact Details

Address:
548 Market Street
San Francisco, Delaware 94104
United States
Phone415 887 2311
Websitebettertx.com

Stock Details

Ticker SymbolBTTX
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS08773T1043
SIC Code7372

Key Executives

NamePosition
Frank L. KarbeChief Executive Officer, Interim Chief Financial Officer, President and Director
David P. Perry M.B.A.Co-Founder and Executive Chairman
Dr. Mark A. Berman M.D.Chief Medical Officer
Kristin WynholdsChief Product Officer
Andres CamachoSenior Vice President of Technology and Head of Engineering
Angela WillisSenior Vice President of Market Access
Jessica MengChief Commercial Officer
Leslie MillerController